X Race against Cancer
Pivotal employees have shown their solidarity again by participating in the X Race Against Cancer held recently in Madrid. The main objective was to raise awareness about the...
News
Pivotal has achieved full accreditation for the Zelta™ (formerly Merative Clinical Development) clinical trials platform
Pivotal has achieved full accreditation for the Zelta™ (formerly Merative Clinical Development) clinical trials platform by @Merative, enabling Pivotal to further advance its technical and operational performance.
...Gene Therapy and Cancer Treatment
Insights Care Magazine (the best global online healthcare magazine) spoke recently with Dr. Óscar Juan, Senior Medical Manager at Pivotal, about Gene Therapy and Cancer Treatment.
“Gene therapy represents a...
Pivotal among the 10 Most Innovative CROs to Watch
Insights Care Magazine (the best global online healthcare magazine) spoke recently with Dr. Ibrahim Farr, Chairman & CEO at Pivotal, about the profound overview of Pivotal’ s...
Race against Cancer
Pivotal employees have shown to be very motivated and active again to participate in the race against Cancer held recently in Madrid. The main goal was to run...
Merry Christmas & Happy New Year
We would like to wish you a Merry Christmas and a Happy New Year as well as to thank you for your confidence and support throughout the years.
...
Pivotal among the 10 Most Reliable CRO´s to Watch
The Insights Care Magazine recently interviewed Dr. Ibrahim Farr, Chairman & CEO at Pivotal, about the company’s journey and how it has developed into...
Pivotal among the 10 Top Pharma Outsourcing Companies in Europe
The Pharma Tech Outlook magazine spoke recently with Dr. Ibrahim Farr, Chairman & CEO at Pivotal, about the company’s overview as already an established European-focused CRO.
“We have...
Pivotal among the 10 Best Healthcare Companies to Watch
The Silicon Review magazine spoke recently with Dr. Ibrahim Farr, Chairman & CEO at Pivotal, about the company’s main services, the new challenges ahead and what will...